Idiopathic Intracranial Hypertension (Pseudotumor Cerebri): Prognosis and Treatment
www.UptoDate.com Mar, Wall, M. & Lee, A.G., 2022
Disturbances of Cerebrospinal Fluid, Including Hydrocephalus, Pseudotumor Cerebri, and Low-Pressure Syndromes, Pseudotumor Cerebri
Adams & Victors Principles of Neurology, Chp 30, pg 628, Ropper, A.H.,et al, 2014
Update on the Pathophysiology and Management of Idiopathic Intracranial Hypertension
JNNP 83:488-494, Biousse,V.,et al, 2012
Diagnosis and New Treatment in Muscle Channelopathies
JNNP 80:360-365, Meola,G.,et al, 2009
Primary Episodic Ataxias:Diagnosis, Pathogenesis and Treatment
Brain 130:2484-2493, Jen, J.C.,et al, 2007
Successful Treatment of Hypnic Headache Syndrome with Acetazolamide
Neurol 61:1157-1158, Sibon,I,et al, 2003
Acetazolamide Treatment for Migraine Aura Status
Neurol 55:1588-1589, Haan,J.,et al, 2000
The Role of Weight Loss and Acetazolamide in the Treatment of Idiopathic Intracranial Hypertension (Pseudotumor Cerebri)
Ophthalmology 105:2313-2317, Johnson,L.N.,et al, 1998
Familial Migraine with Vertigo and Essential Tremor
Neurol 46:458-460, Baloh,R.W.,et al, 1996
Coexistence of Migraine and Idiopathic Intracranial Hypertension without Papilledema
Neurol 46:1226-1230, Mathew,N.T.,et al, 1996
Acetazolamide-Induced Nephrolithiasis:Implications for Treatment of Neuromuscular Disorders
Neurol 43:1105-1106, Tawil,R.,et al, 1993
Idiopathic Intracranial Hypertension:Report of Seven Cases
Am J Med 93:391-395, Jain,N.&Rosner,F., 1992
The Effect of Acetazolamide on Essential Tremor:An Open-Label Trial
Neurol 42:1394-1395, Busenbark,K.,et al, 1992
Acetazolamide-Responsive Vestibulocerebellar Syndrome:Clinical & Oculographic Features
Neurol 41:429-433, Baloh,R.W.&Winder,A., 1991
Chronic Acetazolamide Monotherapy in the Treatment of Juvenile Myoclonic Epilepsy
Neurol 40:1677-1681, Resor,S.R.&Resor,L.D., 1990
The Rational Management of Idiopathic Intracranial Hypertension
Arch Neurol 46:1049-1051, Corbett,J.J.&Thompson,H.S., 1989
Paroxysmal Cerebellar Ataxia
Aust NZ J Med 19:113-117, Feeney,G.F.&Boyle,R.S., 1989
Acetazolamide-Responsive Myotonia Congenita
Neurol 37:488-491, Trudell,R.G.,et al, 1987
Acetazolamide-Responsive Episodic Ataxia Syndrome
Neurol 33:1212-1214, Zasorin,N.L.,et al, 1983
Central Sleep Apnea, Improvement With Acetazolamide Therapy
Arch Int Med 142:1816-1819, White,D.P.,et al, 1982
Acute Effects of Acetazolamide in Hyperkalemic Periodic Paralysis
Neurol 31:725-729, Riggs,J.E.,et al, 1981
Acetazolamide-Induced Improvement in Hydro-cephalus
Arch Neurol 37:376, Donat,J.F., 1980
Familial Periodic Ataxia
Arch Neurol 36:568-569, Donat,J.R.,et al, 1979
Hereditary Paroxysmal Ataxia:Response to Acetazolamide
Neurol 28:1259-1264, Griggs,R.C.,et al, 1978
Effects of Acetazolamide on Myotonia
Ann Neurol 3:531, Griggs,R.C.,et al, 1978
A Syndrome of Early Recognition of Occult Hydrocephalus & Cerebral Atrophy
Quart J Med 183:365, Botez,M.I.,et al, 1977
Hypokalemic Periodic Paralysis withArrhythmia
NEJM 286:253, Levitt,L.,et al, 1972
Effect of Chronic Anticonvulsant Therapy on Serum 25-Hydroxycalciferol Levels in Adults
NEJM 287:898, Hahn,T.,et al, 1972
Carbonic Anhydrase II Deficiency in 12 Families with Osteopetrosis with Renal Tubular Acidosis & Cerebral Calcification
NEJM 313:139-181, Sly,W.S.,et al, 1985
Inhibition of CD40L with Frexalimab in Multiple Sclerosis
NEJM 390:589-600, 662, Vermersch,P.,et al, 2024
Diagnosis and Management of ANCA-Associated Vasculitis
Lancet 403:683-698, Kronbichler, A., et al, 2024
Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients with Atrial Cardiopathy, The ARCADIA Randomized Clinical Trial
JAMA 331:573-581, Kamel,H.,et al, 2024
Repurposing Erectile Dysfunction Medication for Alzheimer Disease Prevention
Neurol 102:e209180, Yasara,S., & Nidadavolu,L., 2024
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Intravenous Thrombolysis in Patients with Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants
JAMA Neurol 80:233-243, 231, Meinel,T.R.,et al, 2023
Progressive Hemiparesis and White Matter Abnormalities in an HIV-Negative Patient
Neurol 100:1156-1163, Jabbari,E.,et al, 2023
Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023
Perioperative Management of Anticoagulant and Antiplatelet Therapy
NEJM Evid doi:10.1056/EVIDna2200322, Douketis,J.D. & Spyropoulos,A.C., 2023
Polymyalgia Rheumatica
Lancet 402:1459-1472, Espigol-Frigole,G.,et al, 2023
Severe Amyloid-Related Imaging Abnormalities After Anti-B-Amyloid Monoclonal Antibody Treatment
Neurol 101:1079-1080, Bonami,S.,et al, 2023
Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors in Patients with Melanoma
Neurol 101:e2472-e2482, Pepys,J.,et al, 2023
Clinicopathologic Conference, Encephalitis due to Behcets Disease
NEJM 387:925-933, Case 27-2022, 2022
In Patients with Melanoma Brain Metastases, is Combination Immune Checkpoint Inhibition a Safe and Effective First-Line Treatment? A Critically Appraised Topic
Neurologist 27:290-297, Gritsch, D.,et al, 2022
Recent Advances in the Diagnosis and Management of Cluster Headache
BMJ 376:e059577, Schindler, E. & Burish, M.J., 2022
Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects
JENDSO 6:1-7, Hamidi, S.,et al, 2022
Atypical Posterior Reversible Encephalopathy Syndrome Associated with Lenvatinib Therapy in a Patient with Metastatic Thyroid-Cancer
Cancer Reports doi:10.1002/cnr2.1605, Abhishek, M.,et al, 2022
A 48-Year-Old Woman with 6 Months of Vivid Visual Hallucinations
Neurol 99:166-171, Kizza, J.,et al, 2022
Neuromyelitis Optica Spectrum Disorder
NEJM 387:631-639, Wingerchuk, D.M. & Lucchinetti, C.F., 2022
Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory
Neurol 98:486-498, Turan, T.N.,et al, 2022